The Experts below are selected from a list of 18 Experts worldwide ranked by ideXlab platform
Stephen L. Sacks - One of the best experts on this subject based on the ideXlab platform.
-
Randomized, Double-Blind, Placebo-Controlled, Clinic-Initiated, Canadian Multicenter Trial of Topical Edoxudine 3.0% Cream in the Treatment of Recurrent Genital Herpes
The Journal of Infectious Diseases, 1991Co-Authors: Stephen L. Sacks, L. D. Tyrrell, D. Lawee, Walter F. Schlech, Michael Gill, Fred Y. Aoki, A. Y. Martel, Joel SingerAbstract:Treatment for recurrent genital herpes using Edoxudine 3% cream for 5 days was evaluated in 200 patients in a randomized, multicenter, double-blind, placebo-controlled, clinic-initiated trial. Lesion tenderness was predictive of and more sensitive and longer-lasting than the symptom of pain. Among patients receiving placebo, times to crusting (P = .043), cessation of investigator-observed signs (P = .005), lesion-associated signs (P = .02), and groin signs (P = .05) were longer in women. Edoxudine reduced viral shedding in men (mean 2.7 vs. 3.4 days, P = .009) and women (2.0 days vs. 3.5 days, P = .0001). Loss of investigator-observed signs (4.4 vs. 6.2 days, P = .002), investigator-observed lesion tenderness (P = .01), lesion signs (P = .02), groin adenopathy (P = .01), and tenderness (P = .01) occurred earlier in women taking Edoxudine. Edoxudine was well-tolerated and reduced several signs of herpes in women. Its clinical role in recurrent genital herpes remains to be fully determined.
-
Randomized, double-blind, placebo-controlled, patient-initiated study of topical high- and low-dose interferon-alpha with nonoxynol-9 in the treatment of recurrent genital herpes
1990Co-Authors: Stephen L. Sacks, L. D. Tyrrell, D. Lawee, Walter F. Schlech, Fred Y. Aoki, A. Y. Martel, John M. Gill, Jeroham Singer, The CanadianAbstract:Treatment for recurrent genital herpes using Edoxudine 3 % cream for 5 days was evaluated in 200 patients in a randomized, multicenter, double-blind, placebo-controlled, clinic-initiated trial. Lesion tenderness was predictive of and more sensitive and longer-lasting than the symp-tom of pain, Among patients receiving placebo, times to crusting (P =.043), cessation of investi-gator-observed signs (P =.005), lesion-associated signs (P =.02), and groin signs (P =.05) were longer in women. Edoxudine reduced viral shedding in men (mean 2.7 vs. 3.4 days, P =.009) and women (2.0 days vs. 3.5 days, P =.0001). Loss of investigator-observed signs (4.4 vs. 6.2 days, P =.002), investigator-observed lesion tenderness (P =.01), lesion signs (P =.02), groin adenopa-thy (P =.01), and tenderness (P =.01) occurred earlier in women taking Edoxudine. Edoxudine was well-tolerated and reduced several signs of herpes in women. Its clinical role in recurrent genital herpes remains to be fully determined. Genital herpes simplex virus (HSV) infection continues to be a major public health concern [1-3]. Although primary infections are more severe, recurrences are far more frequent and may remain troublesome and uncomfortable for the pa
L. D. Tyrrell - One of the best experts on this subject based on the ideXlab platform.
-
Randomized, Double-Blind, Placebo-Controlled, Clinic-Initiated, Canadian Multicenter Trial of Topical Edoxudine 3.0% Cream in the Treatment of Recurrent Genital Herpes
The Journal of Infectious Diseases, 1991Co-Authors: Stephen L. Sacks, L. D. Tyrrell, D. Lawee, Walter F. Schlech, Michael Gill, Fred Y. Aoki, A. Y. Martel, Joel SingerAbstract:Treatment for recurrent genital herpes using Edoxudine 3% cream for 5 days was evaluated in 200 patients in a randomized, multicenter, double-blind, placebo-controlled, clinic-initiated trial. Lesion tenderness was predictive of and more sensitive and longer-lasting than the symptom of pain. Among patients receiving placebo, times to crusting (P = .043), cessation of investigator-observed signs (P = .005), lesion-associated signs (P = .02), and groin signs (P = .05) were longer in women. Edoxudine reduced viral shedding in men (mean 2.7 vs. 3.4 days, P = .009) and women (2.0 days vs. 3.5 days, P = .0001). Loss of investigator-observed signs (4.4 vs. 6.2 days, P = .002), investigator-observed lesion tenderness (P = .01), lesion signs (P = .02), groin adenopathy (P = .01), and tenderness (P = .01) occurred earlier in women taking Edoxudine. Edoxudine was well-tolerated and reduced several signs of herpes in women. Its clinical role in recurrent genital herpes remains to be fully determined.
-
Randomized, double-blind, placebo-controlled, patient-initiated study of topical high- and low-dose interferon-alpha with nonoxynol-9 in the treatment of recurrent genital herpes
1990Co-Authors: Stephen L. Sacks, L. D. Tyrrell, D. Lawee, Walter F. Schlech, Fred Y. Aoki, A. Y. Martel, John M. Gill, Jeroham Singer, The CanadianAbstract:Treatment for recurrent genital herpes using Edoxudine 3 % cream for 5 days was evaluated in 200 patients in a randomized, multicenter, double-blind, placebo-controlled, clinic-initiated trial. Lesion tenderness was predictive of and more sensitive and longer-lasting than the symp-tom of pain, Among patients receiving placebo, times to crusting (P =.043), cessation of investi-gator-observed signs (P =.005), lesion-associated signs (P =.02), and groin signs (P =.05) were longer in women. Edoxudine reduced viral shedding in men (mean 2.7 vs. 3.4 days, P =.009) and women (2.0 days vs. 3.5 days, P =.0001). Loss of investigator-observed signs (4.4 vs. 6.2 days, P =.002), investigator-observed lesion tenderness (P =.01), lesion signs (P =.02), groin adenopa-thy (P =.01), and tenderness (P =.01) occurred earlier in women taking Edoxudine. Edoxudine was well-tolerated and reduced several signs of herpes in women. Its clinical role in recurrent genital herpes remains to be fully determined. Genital herpes simplex virus (HSV) infection continues to be a major public health concern [1-3]. Although primary infections are more severe, recurrences are far more frequent and may remain troublesome and uncomfortable for the pa
D. Lawee - One of the best experts on this subject based on the ideXlab platform.
-
Randomized, Double-Blind, Placebo-Controlled, Clinic-Initiated, Canadian Multicenter Trial of Topical Edoxudine 3.0% Cream in the Treatment of Recurrent Genital Herpes
The Journal of Infectious Diseases, 1991Co-Authors: Stephen L. Sacks, L. D. Tyrrell, D. Lawee, Walter F. Schlech, Michael Gill, Fred Y. Aoki, A. Y. Martel, Joel SingerAbstract:Treatment for recurrent genital herpes using Edoxudine 3% cream for 5 days was evaluated in 200 patients in a randomized, multicenter, double-blind, placebo-controlled, clinic-initiated trial. Lesion tenderness was predictive of and more sensitive and longer-lasting than the symptom of pain. Among patients receiving placebo, times to crusting (P = .043), cessation of investigator-observed signs (P = .005), lesion-associated signs (P = .02), and groin signs (P = .05) were longer in women. Edoxudine reduced viral shedding in men (mean 2.7 vs. 3.4 days, P = .009) and women (2.0 days vs. 3.5 days, P = .0001). Loss of investigator-observed signs (4.4 vs. 6.2 days, P = .002), investigator-observed lesion tenderness (P = .01), lesion signs (P = .02), groin adenopathy (P = .01), and tenderness (P = .01) occurred earlier in women taking Edoxudine. Edoxudine was well-tolerated and reduced several signs of herpes in women. Its clinical role in recurrent genital herpes remains to be fully determined.
-
Randomized, double-blind, placebo-controlled, patient-initiated study of topical high- and low-dose interferon-alpha with nonoxynol-9 in the treatment of recurrent genital herpes
1990Co-Authors: Stephen L. Sacks, L. D. Tyrrell, D. Lawee, Walter F. Schlech, Fred Y. Aoki, A. Y. Martel, John M. Gill, Jeroham Singer, The CanadianAbstract:Treatment for recurrent genital herpes using Edoxudine 3 % cream for 5 days was evaluated in 200 patients in a randomized, multicenter, double-blind, placebo-controlled, clinic-initiated trial. Lesion tenderness was predictive of and more sensitive and longer-lasting than the symp-tom of pain, Among patients receiving placebo, times to crusting (P =.043), cessation of investi-gator-observed signs (P =.005), lesion-associated signs (P =.02), and groin signs (P =.05) were longer in women. Edoxudine reduced viral shedding in men (mean 2.7 vs. 3.4 days, P =.009) and women (2.0 days vs. 3.5 days, P =.0001). Loss of investigator-observed signs (4.4 vs. 6.2 days, P =.002), investigator-observed lesion tenderness (P =.01), lesion signs (P =.02), groin adenopa-thy (P =.01), and tenderness (P =.01) occurred earlier in women taking Edoxudine. Edoxudine was well-tolerated and reduced several signs of herpes in women. Its clinical role in recurrent genital herpes remains to be fully determined. Genital herpes simplex virus (HSV) infection continues to be a major public health concern [1-3]. Although primary infections are more severe, recurrences are far more frequent and may remain troublesome and uncomfortable for the pa
Walter F. Schlech - One of the best experts on this subject based on the ideXlab platform.
-
Randomized, Double-Blind, Placebo-Controlled, Clinic-Initiated, Canadian Multicenter Trial of Topical Edoxudine 3.0% Cream in the Treatment of Recurrent Genital Herpes
The Journal of Infectious Diseases, 1991Co-Authors: Stephen L. Sacks, L. D. Tyrrell, D. Lawee, Walter F. Schlech, Michael Gill, Fred Y. Aoki, A. Y. Martel, Joel SingerAbstract:Treatment for recurrent genital herpes using Edoxudine 3% cream for 5 days was evaluated in 200 patients in a randomized, multicenter, double-blind, placebo-controlled, clinic-initiated trial. Lesion tenderness was predictive of and more sensitive and longer-lasting than the symptom of pain. Among patients receiving placebo, times to crusting (P = .043), cessation of investigator-observed signs (P = .005), lesion-associated signs (P = .02), and groin signs (P = .05) were longer in women. Edoxudine reduced viral shedding in men (mean 2.7 vs. 3.4 days, P = .009) and women (2.0 days vs. 3.5 days, P = .0001). Loss of investigator-observed signs (4.4 vs. 6.2 days, P = .002), investigator-observed lesion tenderness (P = .01), lesion signs (P = .02), groin adenopathy (P = .01), and tenderness (P = .01) occurred earlier in women taking Edoxudine. Edoxudine was well-tolerated and reduced several signs of herpes in women. Its clinical role in recurrent genital herpes remains to be fully determined.
-
Randomized, double-blind, placebo-controlled, patient-initiated study of topical high- and low-dose interferon-alpha with nonoxynol-9 in the treatment of recurrent genital herpes
1990Co-Authors: Stephen L. Sacks, L. D. Tyrrell, D. Lawee, Walter F. Schlech, Fred Y. Aoki, A. Y. Martel, John M. Gill, Jeroham Singer, The CanadianAbstract:Treatment for recurrent genital herpes using Edoxudine 3 % cream for 5 days was evaluated in 200 patients in a randomized, multicenter, double-blind, placebo-controlled, clinic-initiated trial. Lesion tenderness was predictive of and more sensitive and longer-lasting than the symp-tom of pain, Among patients receiving placebo, times to crusting (P =.043), cessation of investi-gator-observed signs (P =.005), lesion-associated signs (P =.02), and groin signs (P =.05) were longer in women. Edoxudine reduced viral shedding in men (mean 2.7 vs. 3.4 days, P =.009) and women (2.0 days vs. 3.5 days, P =.0001). Loss of investigator-observed signs (4.4 vs. 6.2 days, P =.002), investigator-observed lesion tenderness (P =.01), lesion signs (P =.02), groin adenopa-thy (P =.01), and tenderness (P =.01) occurred earlier in women taking Edoxudine. Edoxudine was well-tolerated and reduced several signs of herpes in women. Its clinical role in recurrent genital herpes remains to be fully determined. Genital herpes simplex virus (HSV) infection continues to be a major public health concern [1-3]. Although primary infections are more severe, recurrences are far more frequent and may remain troublesome and uncomfortable for the pa
Fred Y. Aoki - One of the best experts on this subject based on the ideXlab platform.
-
Randomized, Double-Blind, Placebo-Controlled, Clinic-Initiated, Canadian Multicenter Trial of Topical Edoxudine 3.0% Cream in the Treatment of Recurrent Genital Herpes
The Journal of Infectious Diseases, 1991Co-Authors: Stephen L. Sacks, L. D. Tyrrell, D. Lawee, Walter F. Schlech, Michael Gill, Fred Y. Aoki, A. Y. Martel, Joel SingerAbstract:Treatment for recurrent genital herpes using Edoxudine 3% cream for 5 days was evaluated in 200 patients in a randomized, multicenter, double-blind, placebo-controlled, clinic-initiated trial. Lesion tenderness was predictive of and more sensitive and longer-lasting than the symptom of pain. Among patients receiving placebo, times to crusting (P = .043), cessation of investigator-observed signs (P = .005), lesion-associated signs (P = .02), and groin signs (P = .05) were longer in women. Edoxudine reduced viral shedding in men (mean 2.7 vs. 3.4 days, P = .009) and women (2.0 days vs. 3.5 days, P = .0001). Loss of investigator-observed signs (4.4 vs. 6.2 days, P = .002), investigator-observed lesion tenderness (P = .01), lesion signs (P = .02), groin adenopathy (P = .01), and tenderness (P = .01) occurred earlier in women taking Edoxudine. Edoxudine was well-tolerated and reduced several signs of herpes in women. Its clinical role in recurrent genital herpes remains to be fully determined.
-
Randomized, double-blind, placebo-controlled, patient-initiated study of topical high- and low-dose interferon-alpha with nonoxynol-9 in the treatment of recurrent genital herpes
1990Co-Authors: Stephen L. Sacks, L. D. Tyrrell, D. Lawee, Walter F. Schlech, Fred Y. Aoki, A. Y. Martel, John M. Gill, Jeroham Singer, The CanadianAbstract:Treatment for recurrent genital herpes using Edoxudine 3 % cream for 5 days was evaluated in 200 patients in a randomized, multicenter, double-blind, placebo-controlled, clinic-initiated trial. Lesion tenderness was predictive of and more sensitive and longer-lasting than the symp-tom of pain, Among patients receiving placebo, times to crusting (P =.043), cessation of investi-gator-observed signs (P =.005), lesion-associated signs (P =.02), and groin signs (P =.05) were longer in women. Edoxudine reduced viral shedding in men (mean 2.7 vs. 3.4 days, P =.009) and women (2.0 days vs. 3.5 days, P =.0001). Loss of investigator-observed signs (4.4 vs. 6.2 days, P =.002), investigator-observed lesion tenderness (P =.01), lesion signs (P =.02), groin adenopa-thy (P =.01), and tenderness (P =.01) occurred earlier in women taking Edoxudine. Edoxudine was well-tolerated and reduced several signs of herpes in women. Its clinical role in recurrent genital herpes remains to be fully determined. Genital herpes simplex virus (HSV) infection continues to be a major public health concern [1-3]. Although primary infections are more severe, recurrences are far more frequent and may remain troublesome and uncomfortable for the pa
